Atlas
Market PulseMovers & ShakersSector ViewStocksETFFundsPortfoliosAdmin
Atlas › Stocks › ZYDUSLIFE

ZYDUSLIFE

Zydus Lifesciences Limited
Mid-capPharma ↗

What the six lenses say about ZYDUSLIFE — its relative strength vs the baselines, price & RS trend, the 8-quarter financials, and live filings.

Price
₹1156.9
2026-09-08
VWAP · 1Y anchor
₹1023
+13.1% from VWAP
P/E · TTM
23.1×
TTM EPS ₹50.1
52-week range
86%
position low→high
RSI(14)
54
momentum

Own sector index

Pharma ↗
Overweight

1M

+0.4%

3M

+10.5%

1Y

+22.0%

Breadth >EMA21

56%

How ZYDUSLIFE’s own sector index is moving — context for reading the stock’s six lenses.

Six-lens read

What the six lenses say

How the lenses are scored ↗
Strength
5.5
avg conviction decile
Leadership
—
top-decile composite in cohort
Each lens is a decile within its cap cohort (D10 = top 10%) — no black-box composite. Expand a lens for the real numbers behind it.
LensDecile · Mid-cap cohortDRaw
TechnicalD990›

The actual numbers

Price vs VWAP (1y)+13.1%
EMA trend stackUp · 21>50>200
Price vs 200-EMA+11.8%
Price vs 50-EMA+2.9%
RSI(14)54
RS vs Nifty 500 · 3M+1.9%
RS vs sector · 3M-4.1%
52-week range86%
Volume vs 30d avg1.28×
Volume vs 60d avg1.39×
ATR(14) · volatility37.7
Bollinger width · vol contraction0.108
FundamentalD1081›

The actual numbers

Return on equity (ROE)21.2%
Return on capital (ROCE)21.2%
Operating margin26.0%
Net margin18.9%
Revenue growth · YoY+16.8%
EPS growth · YoY+11.4%
Debt / equity0.46×

Full 8-quarter history in the financials table below.

ValuationD835›

The actual numbers

P/E (TTM)23.1×
TTM EPS₹50.1
52-week range86%
CatalystD1089›

The actual numbers

Earnings & momentum153
Capital actions65
Governance180

Every filing in the corporate-announcements panel below.

FlowD242›

The actual numbers

Promoter holding75.0%
Delivery · 30d avg51.8%
Up/down-day asymmetry-3.3pp
How the decile & conviction are calculated

Decile — each lens’s 0–100 score is ranked against every Mid-cap stock in the universe. D10 = top 10% (strongest), D1 = bottom 10%. A decile is simply where this stock sits versus its size-peers on that lens — no weighting, no black box.

Conviction — the average of the two active conviction-lens deciles (Technical & Flow):

( D9 + D2 ) ÷ 2 = 5.5(Technical · Flow)

Fundamental, Catalyst, Valuation and Policy are shown for context but carry weight 0 in the current model, so they are not scored into conviction. Full detail on the methodology page ↗.

Glass box

How the score is built

Click a lens to expand its sub-components, then drill to the actual values. The eye icon on any term explains it.

Conviction score · Highest
85
Conviction score 85/100 · avg-decile strength 5.5/10
Conviction score85/100›
TechnicalD9›
FundamentalD10›
ValuationD8›
CatalystD10›
FlowD2›

Policy

Government policy · Pharma

Active policies relevant to this sector — flagged as a Red / Amber / Green signal, not scored into the six-lens conviction. The lenses say what the market is doing; policy is context for why.

Tailwind· HIGH impact

PLI Scheme — Pharmaceuticals & API

Production-linked incentive scheme for pharmaceuticals, APIs, and medical devices

Relative strength · always on

Percentage-point spread vs each baseline across six windows. Green = outperforming, red = lagging. Data as of 2026-09-08.

Baseline1D1W1M3M6M12M
Nifty 50
Large-cap anchor
+3.8pp
+0.9pp
+7.9pp
+3.5pp
+29.5pp
+18.6pp
Nifty 500
Broad-market baseline
+3.7pp
+0.9pp
+6.8pp
+1.9pp
+23.7pp
+13.4pp
Sector
Own-sector index
—
—
+4.0pp
-4.1pp
+10.6pp
-7.4pp

From atlas_foundation.technical_daily. Sector row covers 1M–12M (1D/1W not stored).

Trend

Price · EMA 20 / 50 / 200

ZYDUSLIFE daily close with the three trend EMAs · atlas_foundation.ohlcv_stock.

₹ (close)
1156.90+36.90

Relative strength

RS vs baseline · rebased to 100

ZYDUSLIFE ÷ Nifty 500, rebased to 100 at window start — above 100 = outperforming since then.

RS vs Nifty 500 (=100)
106.34+3.83

TradingView composite technical analysis — multi-timeframe consensus

Quarterly financials

Last 8 quarters from the company’s filings (₹ crore) — revenue, profit, margins and the growth trend.

MetricJun '24Sep '24Dec '24Mar '25Jun '25Sep '25Dec '25Mar '26
Revenue (₹cr)6,2085,2375,2696,5286,5746,1236,8647,587
↳ change QoQ—-15.6%+0.6%+23.9%+0.7%-6.9%+12.1%+10.5%
EBITDA (₹cr)2,1471,5301,4452,1262,0882,0161,8162,554
EBITDA margin34.6%29.2%27.4%32.6%31.8%32.9%26.5%33.7%
PAT (₹cr)1,4839201,0261,2441,5211,2391,0231,341
↳ change QoQ—-37.9%+11.5%+21.2%+22.3%-18.5%-17.4%+31.1%
Net margin23.9%17.6%19.5%19.1%23.1%20.2%14.9%17.7%
EPS (₹)14.119.0610.1711.6414.5812.5110.3612.65
D/E————————
YoY growth · Mar '26Revenue +16.2% YoYPAT +7.8% YoY

Corporate announcements

Filings to the exchange — capital actions, earnings and governance. Most recent first.

  • 5 Sep '26
    LOWgovernance
    General Updates
    ›

    A governance / disclosure filing — lower signal weight, context only.

    View original filing on NSE ↗
  • 1 Sep '26
    LOWgovernance
    General Updates
    ›

    A governance / disclosure filing — lower signal weight, context only.

    View original filing on NSE ↗
  • 31 Aug '26
    MEDIUMcapital
    Press Release
    ›

    An exchange filing — open the original disclosure on NSE for the full text.

    View original filing on NSE ↗
  • 26 Aug '26
    LOWgovernance
    General Updates
    ›

    A governance / disclosure filing — lower signal weight, context only.

    View original filing on NSE ↗
  • 25 Aug '26
    LOWgovernance
    General Updates
    ›

    A governance / disclosure filing — lower signal weight, context only.

    View original filing on NSE ↗
  • 24 Aug '26
    LOWgovernance
    Updates
    ›

    A governance / disclosure filing — lower signal weight, context only.

    View original filing on NSE ↗
  • 23 Aug '26
    MEDIUMearnings
    Investor Presentation
    ›

    An exchange filing — open the original disclosure on NSE for the full text.

    View original filing on NSE ↗
  • 21 Aug '26
    LOWgovernance
    General Updates
    ›

    A governance / disclosure filing — lower signal weight, context only.

    View original filing on NSE ↗
  • 21 Aug '26
    MEDIUMcapital
    Press Release
    ›

    An exchange filing — open the original disclosure on NSE for the full text.

    View original filing on NSE ↗
  • 18 Aug '26
    LOWgovernance
    Analysts/Institutional Investor Meet/Con. Call Updates
    ›

    A governance / disclosure filing — lower signal weight, context only.

    View original filing on NSE ↗
  • 17 Aug '26
    LOWgovernance
    Analysts/Institutional Investor Meet/Con. Call Updates
    ›

    A governance / disclosure filing — lower signal weight, context only.

    View original filing on NSE ↗
  • 12 Aug '26
    LOWgovernance
    Analysts/Institutional Investor Meet/Con. Call Updates
    ›

    A governance / disclosure filing — lower signal weight, context only.

    View original filing on NSE ↗
  • 11 Aug '26
    MEDIUMgovernance
    Change in Director(s)
    ›

    A governance / disclosure filing — lower signal weight, context only.

    View original filing on NSE ↗
  • 11 Aug '26
    LOWgovernance
    Analysts/Institutional Investor Meet/Con. Call Updates
    ›

    A governance / disclosure filing — lower signal weight, context only.

    View original filing on NSE ↗
  • 11 Aug '26
    LOWgovernance
    Updates
    ›

    A governance / disclosure filing — lower signal weight, context only.

    View original filing on NSE ↗

…and 5 more.

Ownership

Who holds ZYDUSLIFE

Mutual funds holding ZYDUSLIFE (10)

FundWeightAUM ₹crGrade
Parag Parikh Flexi Cap Reg Gr1.46%1,48,429
Kotak Flexicap Reg Gr2.09%56,119
Bandhan Large & Mid Cap Gr1.05%19,777
HSBC Midcap Gr1.18%15,578
Parag Parikh ELSS Tax Saver Reg Gr1.61%5,700
LIC MF Large & Mid Cap Reg Gr1.56%3,133
Sundaram Multi Cap Gr1.04%2,981
HDFC Pharma and Healthcare Reg Gr2.10%2,940
Mahindra Manulife Agrsv Hy Reg Gr0.62%2,634
Sundaram Flexi Cap Reg Gr1.52%1,999

ETFs holding ZYDUSLIFE (10)

ETFWeightGrade
Nippon India Nifty Pharma ETF2.85%
DSP Nifty Healthcare ETF2.46%
Axis NIFTY Healthcare ETF2.45%
Aditya BSL Nifty Healthcare ETF2.45%
ICICI Pru Nifty Healthcare ETF2.45%
Mirae Asset Nifty 500 Healthcare ETF2.03%
Motilal Oswal BSE Healthcare ETF1.76%
DSP Nifty Next 50 ETF1.13%
Mirae Asset Nifty Next50 ETF1.11%
Nippon India ETF Nifty Next 50 Jr BeES1.11%
Show company profile (about, sector, employees, IPO)
Native from atlas_foundation — lens journal, technical_daily, ohlcv_stock; TradingView for the live instrument view. ← Back to Pharma